Pneumococcal Protection

Unvaccinated Baseline — Naive Immune System

No prior exposure. Multiple pneumococcal serotypes circulate freely, unopposed.

• 100+: S. pneumoniae serotypes known (capsular polysaccharide types)
• ~300K: Global IPD deaths per year (children under 5)
• <10: Baseline antibody titer (U/mL, non-protective)
• ~40%: Carriage prevalence (children) (nasopharyngeal colonization)

Capsule diversity drives immune evasion

Polysaccharide capsule shields bacteria from phagocytosis. Over 100 serotypes exist, each antigenically distinct.

Naive antibody levels are non-protective against invasive disease.

Innate defenses alone are insufficient

Complement and neutrophils provide partial control, but capsule resists opsonophagocytosis without antibody.

Who is most at risk

Infants, elderly, and immunocompromised patients lack sufficient baseline immunity to prevent invasive spread.

Vaccination — Conjugate vs Polysaccharide

Two vaccine designs trigger very different immune pathways after injection.

• 13–20: PCV conjugate serotypes (protein-linked polysaccharide)
• 23: PPSV23 serotypes (unconjugated polysaccharide)
• T-dependent: Conjugate response type (engages helper T-cells)
• T-independent: Polysaccharide response (no T-cell help, no boost)

Conjugate design links protein to sugar

Polysaccharide is chemically linked to a carrier protein (e.g. CRM197), enabling T-cell engagement.

Polysaccharide alone bypasses T-cells

Free polysaccharide directly triggers B-cells without helper T-cell signaling — a weaker pathway.

T-cell help is the key difference driving memory formation.

Age-dependent responsiveness

Infants under 2 respond poorly to unconjugated polysaccharide, motivating conjugate vaccine design.

Immune Memory Formation

Antibody titers climb while long-lived memory B-cells accumulate — mainly with conjugate.

• High: Conjugate memory B-cells (long-lived, boostable)
• Low: Polysaccharide memory B-cells (limited, non-boostable)
• ~920: Peak antibody titer (conjugate) (U/mL relative units)
• ~580: Peak antibody titer (polysaccharide) (U/mL relative units)

Germinal centers generate memory

T-cell help drives affinity maturation and class switching, producing durable memory B-cells.

Polysaccharide response plateaus

Without T-cell help, memory pool stays small and repeat doses do not boost titers.

Conjugate memory persists; polysaccharide memory wanes faster.

Booster and recall effects

Conjugate priming enables a rapid anamnestic response upon later antigen exposure.

Pathogen Challenge — Opsonization

Vaccinated hosts meet pneumococcus again. Antibodies coat bacteria for rapid clearance.

• IgG + complement: Opsonization mechanism (marks bacteria for phagocytosis)
• Fast: Clearance speed (conjugate) (high-affinity recall antibody)
• Moderate: Clearance speed (polysaccharide) (lower-affinity, no recall boost)
• Neutrophils: Phagocyte cell type (primary effector cells)

Antibody binding neutralizes capsule shielding

IgG antibodies coat capsular polysaccharide, exposing bacteria to complement and phagocytes.

Speed of response differs by vaccine

Conjugate-primed memory cells mount a faster, stronger recall response than polysaccharide priming.

Faster opsonization reduces bacteremia before dissemination.

Serotype-specific protection only

Protection is limited to serotypes included in the vaccine formulation administered.

Outcome — Reduced Invasive Disease

Effective clearance translates into fewer bacteremia and meningitis cases, plus herd effects.

• ~89%: IPD risk reduction (conjugate) (at peak protection)
• ~57%: IPD risk reduction (polysaccharide) (at peak protection)
• Yes: Herd effect on carriage (conjugate reduces transmission)
• Minimal: Herd effect (polysaccharide) (carriage largely unaffected)

Invasive disease burden falls

Bacteremia and meningitis incidence drop sharply in vaccinated, protected populations.

Conjugate reduces nasopharyngeal carriage

Lower carriage in vaccinated individuals indirectly protects unvaccinated contacts — herd effect.

Herd protection is a hallmark benefit unique to conjugate vaccines.

Durability and booster strategy

Waning protection over time supports scheduled booster doses, especially for polysaccharide recipients.